ENDRA Life Sciences Reviews FDA Meeting; To Update Clinical Study Protocol And Statistical Plan For Submission To FDA As NExt Step Prior To Initiating Study
Portfolio Pulse from Benzinga Newsdesk
ENDRA Life Sciences reviews a constructive FDA meeting and plans to update its clinical study protocol and statistical plan for submission to the FDA before initiating the study.
May 20, 2024 | 12:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ENDRA Life Sciences had a constructive meeting with the FDA and plans to update its clinical study protocol and statistical plan for submission to the FDA before initiating the study.
The positive feedback from the FDA and the planned updates to the clinical study protocol and statistical plan are likely to be viewed favorably by investors, potentially boosting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100